CancerScreen CDx Panels

Highly optimized somatic cancer NGS panel for Companion Diagnostics

Overview

CancerScreen CDx Panels

CancerScreen CDx panel is an NGS assay designed to detect all types of variants from genes specifically associated with somatic cancer and also clinically significant sites, such as TERT promoter. By targeting the selected genes with high sensitivity and specificity enables cost-effective and efficient sequencing.

Also, if the gene of interest does not exist in the panel, it can be added separately through our gene add-on service

Celemic’s CancerScreen CDx Panels can also be accompanied by full Bioinformatics support; the report consists of the primary, secondary, and tertiary results for the in-depth understanding and interpretation of sequencing data.

CancerScreen CDx Panels
Features & Benefits

Optimized Comprehensive Panel for Solid Cancer Analysis

The panel is designed to assess all major mutations for FDA approved therapies and all coding exons in each gene. Using the CancerScreen CDx panel, you can detect all mutation types, including SNV, Indel, Large Inde, CNV, rearrangements relevant to solid cancer in a single assay.

Performance Comparison with Competitor Product

  • Higher on-target ratio, uniformity, coverage at 100X compared to competitor product over the target regions including exons and introns
Performance Comparison with Competitor Product

Superior sensitivity and specificity for both DNA/RNA, even with FFPE or other low-quality clinical samples

CancerScreen CDx panel is suitable for detecting low-frequency and rare variants with high sequencing depths. With Celemics’ proprietary probe design technology, it provides superior capture performance even in so-called difficult to capture regions, such as GC-rich and homologous regions, regardless of the sample types, ranging from blood and tissue to poor-quality FFPE or ctDNA with the highest sensitivity and specificity.

Full Support from FASTQ to Clinical-grade Bioinformatics

Experience our full bioinformatic support and customizable services. Includes pathogenicity, drug-association information, and functional information of target genes.

Bioinformatics and Clinical Report Example

CancerScreen CDx Panels

Rapid and Easy-to-use Workflow

Expedite sequencing with no compromise on data quality with rapid one-day protocol. Celemics provides simplified version of NGS workflow with no need for heavy instruments. The experimental procedure are also compatible with various automotive liquid handlers for your convenience.

Newly Developed Same-day Workflow

Newly Developed Same-Day Workflow

Conventional
workflow
» 20 hours

Library Prep

Target Capture

Newly Developed Same-Day Workflow

Same-day
workflow
» 5-8 hours

Library Prep

Target Capture

Specification

Product Name CancerScreen CDx DNA Kit CancerScreen CDx RNA Kit CancerScreen CDx HRD Kit
Gene count 22 9 15
Target size 73.4 kb 32.1 kb 69.4 kb
Mutation type SNV, Indel, CNV, Rearrangement
Covered region Whole CDS, Rearrangement
Sample Type FFPE, Fresh tissue, etc.
Platform All sequencers from Illumina and Thermo Fisher
Bioinformatics Support ① Primary Analysis: FASTQ to annotated VCF
② Secondary Analysis: CNV, Large InDel, TMB & MSI
③ Tertiary Analysis: Clinical interpretation
Visualization Curation (Heatmap, CNV visualization, Statistical analysis, etc.)

Specification - Gene List

  • 22 genes | Gene count
  • 73.4 kb | Target Size
DNA Panel ALK BRAF BRCA1 BRCA2 EGFR ERBB2
EZH2 FGFR3 FLT3 IDH2 IDH2 KIT
KRAS MET MYC MYCN NF1 NRAS
PDGFRA PDGFRB PIK3CA TP53    
  • 9 genes | Gene count
  • 32.1 kb | Target Size
RNA Panel ABL1 ALK FGFR2 FGFR3 NTRK1 NTRK2
NTRK3 RET ROS1      
  • 15 genes | Gene count
  • 69.4 kb | Target Size
HRD Panel ARID1A ATM ATRX BAP1 BLM BRCA1
BRCA2 BRIP1 CHEK2 FANCC MRE11 NBN
PALB2 RAD50 WRN      

Related Products

Ready-to-use-panel

Designed to detect all types of variants and immuno-oncology markers including gene rearrangement in various somatic cancer-related and cancer-associated genes

Ready-to-use-panel

Comprehensive and specialized hereditary cancer panel for analyzing 31 oncogenes associated with inherited cancer

Ready-to-use-panel

Designed to detect all types of variants including gene rearrangement in various somatic cancer-related genes

Celemics Analysis Service

End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis

Resources

Technical Resources

Flyer_CancerScreen CDx Panel

Product Overview] Celemics Target Enrichment Panel Overview

[Catalogue] Celemics Products & Service Catalogue_All Products & Service

Safety Data Sheets

MSDS_CancerScreen CDx Panels_Illumina_Enzymeplus

MSDS_CancerScreen CDx Panels_Illumina

MSDS_CancerScreen CDx Panels_Thermo Fisher

MSDS_CancerScreen CDx Panels_MGI_EnzymePlus

MSDS_CancerScreen CDx Panels_MGI

References

Epigenomics

Identification of tissue of origin in cancer of unknown primary using a targeted bisulfite sequencing panel

Bae JM, Ahn JY, Lee H, Jang H, Han H, Jeong J, et al. Identification of tissue of origin in cancer of unknown primary using a targeted bisulfite sequencing panel. Epigenomics. 2022 May;14(10):615–28.

 

10.2217/epi-2021-0477


View Detail >

Investig Clin Urol

Germline pathogenic variants in unselected Korean men with prostate cancer

So MK, Ahn HK, Huh J, Kim KH. Germline pathogenic variants in unselected Korean men with prostate cancer. Investig Clin Urol. 2022 May;63(3):294–300.

 

DOI 10.4111/icu.20220044


View Detail >

Scientific Reports

Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers

Lee J, Ham JY, Park HY, Jung JH, Kim WW, Kang B, et al. Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers. Sci Rep. 2022 Feb 3;12(1):1842.

 

DOI 10.1038/s41598-022-05931-3


View Detail >

BMC Medical Genomics

A novel bi-alleleic DDX41 mutations in B-cell lymphoblastic leukemia: case report

Shin WY, Yoon SY, Park R, Kim JA, Song HH, Bang HI, et al. A novel bi-alleleic DDX41 mutations in B-cell lymphoblastic leukemia: case report. BMC Med Genomics. 2022 Mar 4;15(1):46.

 

DOI 10.1186/s12920-022-01191-2


View Detail >